Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's RVT-3101?
RVT-3101 is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Data Insights
RVT-3101 by F. Hoffmann-La Roche for Crohn's Disease (Regional Enteritis): Likelihood of Approval
RVT-3101 is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Crohn's Disease (Regional Enteritis). According...